Loading...
01/10 23:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
Revenue $30.5 million, a 38% increase year-over-year.
Net Income $5.1 million, year-over-year change not specified.
Cash from Operations $7.9 million, year-over-year change not specified.
Cash Balance $55.6 million, no debt.
E-commerce Net Sales $16.8 million, a 31% increase year-over-year.
Food Grade and Pharmaceutical Grade Niagen Ingredient Business $8 million, a 95% increase year-over-year.
Revenue Growth: In the first quarter, Niagen Bioscience delivered $30.5 million in revenue, a 38% year-over-year increase.
E-commerce Sales: E-commerce continued to be a main driver of top-line growth with net sales of $16.8 million, a 31% increase year-over-year.
Niagen Ingredient Business: The food grade and pharmaceutical grade Niagen ingredient business grew to $8 million, a 95% increase year-over-year.
Cash Generation: Generated $7.9 million of cash from operations.
Cash Position: Ended the quarter with $55.6 million in cash and no debt.
Rebranding: This is the first investor call as Niagen Bioscience, formerly known as ChromaDex.
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
Regulatory risks: The timing of future regulatory filings and the results of clinical trials are uncertain, which could impact business development opportunities.
Market conditions: Global market and economic conditions may affect the company's operations, financial conditions, and cash flows.
Competitive pressures: The company faces competitive pressures in the market, which could impact its growth and revenue.
Financial performance: The company’s financial results are subject to fluctuations that could affect investor interest and business prospects.
Revenue Growth: In Q1 2025, Niagen Bioscience reported $30.5 million in revenue, a 38% year-over-year increase.
Net Income: The company achieved a net income of $5.1 million in Q1 2025.
Cash from Operations: Generated $7.9 million of cash from operations in Q1 2025.
E-commerce Growth: E-commerce sales reached $16.8 million, a 31% increase year-over-year.
Ingredient Business Growth: Food grade and pharmaceutical grade Niagen ingredient business grew to $8 million, a 95% increase year-over-year.
Cash Position: Ended Q1 2025 with $55.6 million in cash and no debt.
Future Outlook: The company anticipates continued growth in e-commerce and ingredient sales, with plans for expansion into new markets.
Share Buyback Program: The company has initiated a share buyback program, allocating $10 million for the repurchase of shares.
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
The earnings call reveals strong financial performance with a 38% YoY revenue increase, improved gross margins, and a significant net income turnaround. The company also raised its revenue growth outlook to 20%-25%. Despite competitive pressures, the launch of NIAGEN IV and plans for market expansion are promising. The Q&A section highlighted strong interest in new products, although some promotional strategies remain unclear. The lack of debt and strong cash position further enhance financial stability. Overall, the positive financial metrics and optimistic guidance outweigh the concerns, suggesting a positive stock price reaction.
The earnings call shows strong financial performance, with a significant turnaround in net income and improved margins. The Q&A section highlights growth in new customer acquisition and potential market expansion, although some uncertainties remain regarding study results and supply chain issues. Overall, the financial health and growth prospects suggest a positive outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
